Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection

Clinical Transplantation

Volumn 15, Issue 5, 2001, Pages 297-308

  Tornatore, Kathleen M ^a,b,c   Garey, Kevin W ^a   Saigal, Navid ^b,c   Reed, Kris ^b,c   Murray, Brian ^b,c   Ingalls, Elizabeth ^a   Difrancesco, Robin ^a   Forrest, Alan ^a   Morse, Gene ^a,b,c   Venuto, Rocco ^b,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ERIE COUNTY MEDICAL CENTER   (United States)

Author keywords

Cytokines; Cytomegalovirus; Ganciclovir; Kidney transplantation

Indexed keywords

ANTIVIRUS AGENT; CREATININE; CYTOKINE; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

BLOOD LEVEL; BLOOD SAMPLING; CALCULATION; CASE REPORT; CLINICAL TRIAL; COMPARTMENT MODEL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE; DRUG RESPONSE; DYNAMICS; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE EXCRETION; MALE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RECIPIENT; REVIEW; VIREMIA;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; BAYES THEOREM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; CYTOKINES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY TRANSPLANTATION; LINEAR MODELS; MALE;

EID: 0034785269     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2001.150501.x     Document Type: Review

References (44)

1. Cytomegalovirus infections following renal transplantation
2. Advances in understanding cytomegalovirus infection after transplantation
3. Which renal transplant patients should receive cytomegalovirus immune globulin?
4. Management and prevention of cytomegalovirus infection after renal transplantation
5. Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy
6. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy
7. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation
8. Late-acute renal allograft rejection and symptomess cytomegalovirus infection
9. The cytomegalovirus-antigenemia assay in diagnosis of post-transplant cytomegalovirus infection
10. Direct detection of cytomegalovirus in peripheral blood leukocytes: A review of the antigenemia assay and polymerase chain reaction
11. Cytokine monitoring of infection and rejection in renal transplant recipients
12. Cytomegalovirus infection in transplant recipients: The role of tumor necrosis factor
13. Association between CMV-related graft injury and circulating cytokine-producing CD8+ memory cells
14. Plasma IL-2 levels and diagnosis of renal transplant rejection
15. Interleukin 6 (IL-6) in serum and urine of renal transplant recipients
16. Ganciclovir
17. Prediction of creatinine clearance from serum creatinine
18. Serum monitoring of ganciclovir
19. Human pharmacokinetics of the antiviral drug DHPG
20. Ganciclovir pharmacokinetics during renal impairment
21. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function
22. Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis
23. HPLC determination of serum ganciclovir using ultrafiltration, ultraviolet, and fluorescence detection
24. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes
25. Detection of human cytomegalovirus immediate-early antigen in leukocytes as a marker of viremia in immunocompromised patients
26. A program package for simulation and parameter estimation in pharmacokinetic systems
27. Analysis of clinical pharmacokinetic data for individualizing drug dosage regimens
28. Pharmacokinetics
29. LAGRAN program for area and moments in pharmacokinetic analysis: Computer methods and programs
30. Gentamicin therapy
31. Bedside estimation of creatinine clearance: Which method is most accurate and least complex?
32. Ganciclovir absolute bioavailability and steady state pharmacokinetics after oral administration of two 3000 mg/day dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients
33. Human pharmacokinetics and tolerance of oral ganciclovir
34. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: A phase I/II study
35. Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease
36. Predicting glomerular filtration rate after kidney transplantation
37. Use of the serum creatinine to estimate glomerular filtration rate in healthy and early diabetic nephropathy
38. The value of posttransplant monitoring of interleukin (IL)-2, IL-3, IL-4, IL-6, IL-8, and soluble CD23 in the plasma of renal allograft recipients
39. Cyclosporin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders
40. Corticosteriods inhibit murine macrophage Ia expression and interleukin 1 production
41. Effect of mycophenolate mofetil (RS-61443) on cytokine production: Inhibition of superantigen-induced cytokines
42. Intragraft expression of IL-10 messenger RNA: A novel correlate of renal allograft rejection
43. The biology of interleukin-6